Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not recommended. Here, we detail the effect of pexida...

Descripción completa

Detalles Bibliográficos
Autores principales: Van De Sande, Michiel, Tap, William D, Gelhorn, Heather L, Ye, Xin, Speck, Rebecca M, Palmerini, Emanuela, Stacchiotti, Silvia, Desai, Jayesh, Wagner, Andrew J, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Wang, Qiang, Shuster, Dale, Gelderblom, Hans, Healey, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382018/
https://www.ncbi.nlm.nih.gov/pubmed/33977825
http://dx.doi.org/10.1080/17453674.2021.1922161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382018/
https://www.ncbi.nlm.nih.gov/pubmed/33977825
http://dx.doi.org/10.1080/17453674.2021.1922161

Ejemplares similares